Micro Identification Technologies Receives Additional Funding
Published: Sep 29, 2010
SAN CLEMENTE, CA--(Marketwire - September 29, 2010) - Micro Identification Technologies, Inc. (OTCBB: MMTC) (MIT) announces that it has entered into a Securities Purchase Agreement in the form of an 8% convertible note with a New York-based privately held investment banking firm. The Note matures on May 18, 2011 and is convertible into common shares. The firm may convert any or the entire unpaid principal note prior to the maturity date, commencing 180 days following the date of the Note.
This funding is in addition to our recent announcement of the equity financing commitment from Dutchess Capital. MIT expects to receive additional funding from this or other firms under similar conditions in the upcoming months to accelerate its planned production launch and marketing campaign later this year. MIT's Chairman and CEO, Michael Brennan, stated, "This funding will significantly help MIT achieve its near term goals and, together with expected future funding, will enable MIT to exceed its short and medium term plans."
MIT will be hosting a Webinar at 1:00 PM PDT today to provide an update of its current business and future plans. Attendees may register for this Event at: https://www3.gotomeeting.com/register/427693966
About Micro Identification Technologies:
MIT is a California-based public company that has developed and patented a rapid microbial identification (ID) System that revolutionizes the pathogenic bacteria ID process and can annually save thousands of lives and tens of millions of dollars. The System IDs bacteria in minutes, not days, and at a significant per test cost savings when compared to any conventional method. It does not rely on chemical or biological agents, conventional processing, fluorescent tags, gas chromatography or DNA analysis. The process is totally GREEN requiring only clean water and a sample of the unknown bacteria. Revenues for all rapid testing methods exceed $5 billion annually -- with food safety accounting for over $3 billion -- having expanded at a rate of 9.2 percent annually since 1998. Current growth projections are at 30 percent annually with test demands driven by major health, safety and homeland security issues. www.micro-identification.com
MIT has demonstrated the ability to detect and identify, within several minutes, the microbes Escherichia coli, Listeria, Salmonella, Staphylococcus aureus, and other pathogenic bacteria. MIT has performed over 300 tests for the identification of the aforementioned contaminants and scored 95% accuracy. The System can currently identify 23 species of bacteria and is easily expandable. The identification process has been verified by North American Science Associates, Inc. (NAMSA), an independent, internationally recognized biological testing laboratory. The NAMSA Test Report is available from the Company and, in MIT's opinion, demonstrates the accuracy, speed and cost effectiveness of the System over conventional processes. www.namsa.com
This release contains statements that are forward-looking in nature. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions are forward-looking statements. These statements are made based upon information available to the Company as of the date of this release, and we assume no obligation to update any such forward-looking statements. These statements are not guarantees of future performance and actual results could differ materially from our current expectations. Factors that could cause or contribute to such differences include, but are not limited to dependence on suppliers; short product life cycles and reductions in unit selling prices; delays in development or shipment of new products; lack of market acceptance of our new products or services; inability to continue to develop competitive new products and services on a timely basis; introduction of new products or services by major competitors; our ability to attract and retain qualified employees; inability to expand our operations to support increased growth; and declining economic conditions, including a recession. These and other factors and risks associated with our business are discussed from time to time within our filings with the Securities and Exchange Commission.
Email: Email Contact
Telephone: (805) 557-0614